Published in Neoplasia on November 01, 2012
Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Transl Oncol (2014) 0.87
Ghrelin O-acyltransferase (GOAT) is expressed in prostate cancer tissues and cell lines and expression is differentially regulated in vitro by ghrelin. Reprod Biol Endocrinol (2013) 0.83
Enhanced UV-induced skin carcinogenesis in transgenic mice overexpressing proprotein convertases. Neoplasia (2013) 0.83
PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation. Oncotarget (2015) 0.81
Effect of Furin inhibitor on lung adenocarcinoma cell growth and metastasis. Cancer Cell Int (2014) 0.79
Myeloid cell expressed proprotein convertase FURIN attenuates inflammation. Oncotarget (2016) 0.78
PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor. Neoplasia (2014) 0.78
Cancer subclonal genetic architecture as a key to personalized medicine. Neoplasia (2013) 0.78
Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6). Mol Carcinog (2014) 0.77
Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity. Biomed Res Int (2015) 0.76
Regulation of HIF-1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cells. Mol Carcinog (2014) 0.75
Expression of paired basic amino acid-cleaving enzyme 4 (PACE4) correlated with prognosis in non-small cell lung cancer (NSCLC) patients. J Thorac Dis (2015) 0.75
Proprotein convertase inhibition: Paralyzing the cell's master switches. Biochem Pharmacol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68
Targeted cancer therapy. Nature (2004) 7.81
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer (2008) 6.22
Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer (2008) 4.30
The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol (2004) 3.34
Why do hubs tend to be essential in protein networks? PLoS Genet (2006) 3.29
The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov (2012) 3.18
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development (1998) 1.98
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer (2008) 1.70
Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagn Pathol (2007) 1.70
Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol (2010) 1.61
EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis (1996) 1.57
SPC4/PACE4 regulates a TGFbeta signaling network during axis formation. Genes Dev (2000) 1.56
Limited redundancy of the proprotein convertase furin in mouse liver. J Biol Chem (2004) 1.52
Integrins and prostate cancer metastases. Cancer Metastasis Rev (2001) 1.51
Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol (2002) 1.46
Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res (1992) 1.43
Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol (2011) 1.43
Regulation of prostatic growth and function by peptide growth factors. Prostate (1996) 1.42
Growth factor involvement in progression of prostate cancer. Clin Chem (1998) 1.35
In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis (1995) 1.32
Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J (2007) 1.24
Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol (2010) 1.22
MMP inhibition in prostate cancer. Ann N Y Acad Sci (1999) 1.21
CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol (1998) 1.16
Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer (1988) 1.10
Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer (1998) 1.10
Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1. Cancer Res (2007) 1.09
Molecular Validation of PACE4 as a Target in Prostate Cancer. Transl Oncol (2011) 1.05
PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res (2005) 1.04
On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomol Concepts (2011) 1.02
Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4. Carcinogenesis (2002) 0.98
A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Ann Rheum Dis (2012) 0.94
MMTV-cre-mediated fur inactivation concomitant with PLAG1 proto-oncogene activation delays salivary gland tumorigenesis in mice. Int J Oncol (2008) 0.93
Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer (2011) 0.92
Growth factors and their receptors: new targets for prostate cancer therapy. Urology (2001) 0.92
Transgenic overexpression of the proprotein convertase furin enhances skin tumor growth. Neoplasia (2012) 0.91
Proprotein convertase PC7 enhances the activation of the EGF receptor pathway through processing of the EGF precursor. J Biol Chem (2011) 0.91
Prostate cancer regulatory networks. J Cell Biochem (2009) 0.91
Suppression of latent transforming growth factor (TGF)-beta1 restores growth inhibitory TGF-beta signaling through microRNAs. J Biol Chem (2011) 0.90
Subtilisin-like proprotein convertase PACE4 is required for skeletal muscle differentiation. J Biochem (2009) 0.89
Furin overexpression suppresses tumor growth and predicts a better postoperative disease-free survival in hepatocellular carcinoma. PLoS One (2012) 0.88
Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev (1993) 0.86
Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Prostate (2003) 0.84
Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo. Endocr Relat Cancer (2009) 0.82
Androgen receptor-mediated growth and epidermal growth factor receptor induction in the human prostate cell line LNCaP. Urol Int (1989) 0.80
Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem (2009) 2.57
Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res (2007) 1.52
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem (2009) 1.49
Furin processing and proteolytic activation of Semliki Forest virus. J Virol (2003) 1.40
Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem (2008) 1.40
Loss of hepatocyte-nuclear-factor-4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice. PLoS One (2009) 1.32
Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains. J Biol Chem (2001) 1.32
Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci (2005) 1.27
MALDI imaging mass spectrometry: state of the art technology in clinical proteomics. Mol Cell Proteomics (2009) 1.25
Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem (2009) 1.20
At the crossroads of homoeostasis and disease: roles of the PACS proteins in membrane traffic and apoptosis. Biochem J (2009) 1.15
TACE/ADAM-17 maturation and activation of sheddase activity require proprotein convertase activity. FEBS Lett (2003) 1.15
Analysis of peptides in prohormone convertase 1/3 null mouse brain using quantitative peptidomics. J Neurochem (2010) 1.15
The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PLoS One (2010) 1.10
Hepatocyte nuclear factor 4alpha contributes to an intestinal epithelial phenotype in vitro and plays a partial role in mouse intestinal epithelium differentiation. Am J Physiol Gastrointest Liver Physiol (2009) 1.10
Hepatocyte nuclear factor-4alpha promotes gut neoplasia in mice and protects against the production of reactive oxygen species. Cancer Res (2010) 1.09
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem (2007) 1.08
Phenylpropanoids, phenylalanine ammonia lyase and peroxidases in elicitor-challenged cassava (Manihot esculenta) suspension cells and leaves. Ann Bot (2004) 1.06
Identification and characterization of three members of the human metallocarboxypeptidase gene family. J Biol Chem (2002) 1.06
Direct analysis of neuropeptides by in situ MALDI-TOF mass spectrometry in the rat brain. Neuro Endocrinol Lett (2003) 1.06
Molecular Validation of PACE4 as a Target in Prostate Cancer. Transl Oncol (2011) 1.05
Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem (2010) 1.05
Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J Biol Chem (2011) 1.03
On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomol Concepts (2011) 1.02
Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia (2012) 1.02
New bicyclic cannabinoid receptor-1 (CB1-R) antagonists. Bioorg Med Chem Lett (2005) 1.02
Modification in oxidative stress, inflammation, and lipoprotein assembly in response to hepatocyte nuclear factor 4alpha knockdown in intestinal epithelial cells. J Biol Chem (2010) 1.02
Epithelial phosphatase and tensin homolog regulates intestinal architecture and secretory cell commitment and acts as a modifier gene in neoplasia. FASEB J (2009) 1.01
Hepatocyte nuclear factor-4alpha promotes differentiation of intestinal epithelial cells in a coculture system. Am J Physiol Gastrointest Liver Physiol (2007) 1.00
Biosynthesis of proopiomelanocortin-derived peptides in prohormone convertase 2 and 7B2 null mice. Endocrinology (2003) 1.00
MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Med Sci Monit (2010) 0.99
Furin is the major processing enzyme of the cardiac-specific growth factor bone morphogenetic protein 10. J Biol Chem (2011) 0.99
Ovarian cancer molecular pathology. Cancer Metastasis Rev (2012) 0.98
Cdx2 modulates proliferation in normal human intestinal epithelial crypt cells. Biochem Biophys Res Commun (2006) 0.98
Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem (2012) 0.98
Cooperation between HNF-1alpha, Cdx2, and GATA-4 in initiating an enterocytic differentiation program in a normal human intestinal epithelial progenitor cell line. Am J Physiol Gastrointest Liver Physiol (2010) 0.97
Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site. PLoS One (2009) 0.97
Targeted ablation of the chromogranin a (Chga) gene: normal neuroendocrine dense-core secretory granules and increased expression of other granins. Mol Endocrinol (2006) 0.96
The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem (2012) 0.96
Optimization of protease-inhibitor interactions by randomizing adventitious contacts. Proc Natl Acad Sci U S A (2003) 0.95
Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer. Anal Bioanal Chem (2011) 0.92
New developments in MALDI imaging for pathology proteomic studies. Curr Pharm Des (2007) 0.92
Furin is the primary in vivo convertase of angiopoietin-like 3 and endothelial lipase in hepatocytes. J Biol Chem (2013) 0.91
Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice. Mol Cell Biol (2013) 0.91
HDAC1 and HDAC2 restrain the intestinal inflammatory response by regulating intestinal epithelial cell differentiation. PLoS One (2013) 0.90
Loss of hepatocyte-nuclear-factor-1alpha impacts on adult mouse intestinal epithelial cell growth and cell lineages differentiation. PLoS One (2010) 0.90
Intestinal fatty acid binding protein regulates mitochondrion beta-oxidation and cholesterol uptake. J Lipid Res (2008) 0.90
Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol Pharmacol (2006) 0.90
Disruption of the expression of the proprotein convertase PC7 reduces BDNF production and affects learning and memory in mice. Proc Natl Acad Sci U S A (2013) 0.89
Development of liquid microjunction extraction strategy for improving protein identification from tissue sections. J Proteomics (2013) 0.89
Procedural sedation practices in Australian Emergency Departments. Emerg Med Australas (2011) 0.89
Silencing of SPC2 expression using an engineered delta ribozyme in the mouse betaTC-3 endocrine cell line. J Biol Chem (2004) 0.89
Constitutive activation of the MEK/ERK pathway inhibits intestinal epithelial cell differentiation. Am J Physiol Gastrointest Liver Physiol (2011) 0.89
Disruption of proprotein convertase 1/3 (PC1/3) expression in mice causes innate immune defects and uncontrolled cytokine secretion. J Biol Chem (2012) 0.88
The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J Med Chem (2012) 0.88
Loss of Smad5 leads to the disassembly of the apical junctional complex and increased susceptibility to experimental colitis. Am J Physiol Gastrointest Liver Physiol (2011) 0.87
Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency. Arch Biochem Biophys (2005) 0.87
Lipopolysaccharide mediated regulation of neuroendocrine associated proprotein convertases and neuropeptide precursor processing in the rat spleen. J Neuroimmunol (2005) 0.86
A spectrometer designed for 6.7 and 14.1 T DNP-enhanced solid-state MAS NMR using quasi-optical microwave transmission. J Magn Reson (2011) 0.86
Inhibitors of the subtilase-like pro-protein convertases (SPCs). Curr Pharm Des (2002) 0.85
Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int J Biochem Cell Biol (2010) 0.84
Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells. Methods Mol Biol (2014) 0.82
Group VIA phospholipase A2 mediates enhanced macrophage migration in diabetes mellitus by increasing expression of nicotinamide adenine dinucleotide phosphate oxidase 4. Arterioscler Thromb Vasc Biol (2014) 0.82
Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem (2013) 0.82
Effects of a herbal extract on the bone density, strength and markers of bone turnover of mature ovariectomized rats. Am J Chin Med (2003) 0.82
The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling. Histochem Cell Biol (2012) 0.82
Risk factors for sedation-related events during procedural sedation in the emergency department. Emerg Med Australas (2011) 0.82
Oxidative stress and mitochondrial functions in the intestinal Caco-2/15 cell line. PLoS One (2010) 0.82
Processing of proendothelin-1 by members of the subtilisin-like pro-protein convertase family. FEBS Lett (2002) 0.82
Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin. J Med Chem (2013) 0.81
Factors influencing social and health outcomes after motor vehicle crash injury: an inception cohort study protocol. BMC Public Health (2014) 0.81
Identification of a novel promyelocytic leukemia zinc-finger isoform required for colorectal cancer cell growth and survival. Int J Cancer (2013) 0.81
Natural bone collagen scaffold combined with autologous enriched bone marrow cells for induction of osteogenesis in an ovine spinal fusion model. Tissue Eng Part A (2009) 0.81
The perils of pet ownership: a new fall-injury risk factor. Med J Aust (2004) 0.80
Proteomic analyses of serous and endometrioid epithelial ovarian cancers - cases studies - molecular insights of a possible histological etiology of serous ovarian cancer. Proteomics Clin Appl (2013) 0.79
Quantification-based mass spectrometry imaging of proteins by parafilm assisted microdissection. Anal Chem (2013) 0.79
Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. J Clin Invest (2016) 0.79
Proprotein convertase 1/3 (PC1/3) in the rat alveolar macrophage cell line NR8383: localization, trafficking and effects on cytokine secretion. PLoS One (2013) 0.78
Strain-specific steroidal control of pituitary function. J Endocrinol (2007) 0.78
Processing and trafficking of a prohormone convertase 2 active site mutant. Biochem Biophys Res Commun (2007) 0.78